@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix Protein: . @prefix rgd: . @prefix geneProductOf: . @prefix mesh: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: rgd:619869; a Protein: . sub:_2 occursIn: mesh:D008168, species:10116; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject chebi:6494; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:lipopolysaccharide) -> p(RGD:Cxcl1)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "1.4" . sub:_3 prov:value "LPS exposure caused a significant increase in pro-inflammatory mediators in the lung tissue (Fig. 3 and Table 2). Although resveratrol did not have a general inhibitory effect on proinflammatory mediators, it did cause a dose-related inhibition of TNF-?, IL-1?, MPO, and CINC-1 levels in the lung tissue (Fig. 3 and Table 2). The positive control, budesonide, caused similar dose-related inhibition of all of the pro-inflammatory proteins increased by LPS treatment (Fig. 3 and Table 2)."; prov:wasQuotedFrom pubmed:15734790 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:15734790; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:32.848+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }